DPYD Gene Dihydropyrimidine dehydrogenase deficiency Genetic Test
Genetic testing plays a crucial role in identifying and understanding various genetic conditions. One such condition is DPYD gene dihydropyrimidine dehydrogenase deficiency (DPD deficiency), which affects the body’s ability to break down and eliminate certain medications, particularly those containing fluoropyrimidines. This condition is commonly observed in individuals undergoing cancer treatment.
Test Details
The DPYD gene NGS genetic test analyzes the DPYD gene for mutations or variations that may be associated with DPD deficiency. This test utilizes Next-generation sequencing (NGS) technology, which allows for the simultaneous analysis of multiple genes, including DPYD, in a more efficient and cost-effective manner compared to traditional sequencing methods.
The DPYD gene provides instructions for producing the enzyme dihydropyrimidine dehydrogenase (DPD), responsible for breaking down fluoropyrimidines. Mutations in the DPYD gene can lead to reduced or absent DPD enzyme activity, resulting in the accumulation of toxic levels of fluoropyrimidines in the body.
Test Components and Price
The DPYD Gene Dihydropyrimidine dehydrogenase deficiency Genetic Test costs AED 4400.0. The test can be performed using blood or extracted DNA, or even one drop of blood on an FTA Card.
Report Delivery and Test Method
The report for the DPYD Gene Dihydropyrimidine dehydrogenase deficiency Genetic Test is typically delivered within 3 to 4 weeks. The test utilizes NGS technology for analysis.
Test Type and Doctor
The DPYD Gene Dihydropyrimidine dehydrogenase deficiency Genetic Test falls under the category of Metabolic Disorders. It is recommended to consult with a General Physician for this test.
Test Department and Pre-Test Information
The DPYD Gene Dihydropyrimidine dehydrogenase deficiency Genetic Test is conducted by the Genetics department. Prior to the test, it is essential to provide the clinical history of the patient who is undergoing the test. Additionally, a Genetic Counselling session is conducted to draw a pedigree chart of family members affected by Dihydropyrimidine dehydrogenase deficiency.
Importance and Benefits of DPYD Gene NGS Genetic Testing
NGS genetic testing for DPYD gene mutations can help identify individuals who may be at risk for DPD deficiency and may experience severe side effects from fluoropyrimidine-based medications. This information can be used to guide treatment decisions, including dosage adjustments or the selection of alternative medications, to minimize the risk of adverse reactions.
It is important to note that DPD deficiency is a rare condition, and not all individuals with DPYD gene mutations will necessarily develop severe side effects. Therefore, the decision to undergo DPYD gene NGS genetic testing should be made in consultation with a healthcare professional who can assess the individual’s specific circumstances and medical history.
| Test Name | DPYD Gene Dihydropyrimidine dehydrogenase deficiency Genetic Test |
|---|---|
| Components | |
| Price | 4400.0 AED |
| Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card |
| Report Delivery | 3 to 4 Weeks |
| Method | NGS Technology |
| Test type | Metabolic Disorders |
| Doctor | General Physician |
| Test Department: | Genetics |
| Pre Test Information | Clinical History of Patient who is going for DPYD Gene Dihydropyrimidine dehydrogenase deficiency NGS Genetic DNA Test A Genetic Counselling session to draw a pedigree chart of family members affected with Dihydropyrimidine dehydrogenase deficiency |
| Test Details |
DPYD gene dihydropyrimidine dehydrogenase deficiency (DPD deficiency) is a genetic condition that affects the body’s ability to break down and eliminate certain medications, particularly those containing fluoropyrimidines. These medications are commonly used in the treatment of cancer. DPYD gene NGS genetic testing is a type of genetic test that analyzes the DPYD gene for mutations or variations that may be associated with DPD deficiency. Next-generation sequencing (NGS) technology allows for the simultaneous analysis of multiple genes, including DPYD, in a more efficient and cost-effective manner compared to traditional sequencing methods. The DPYD gene provides instructions for producing the enzyme dihydropyrimidine dehydrogenase (DPD), which is responsible for breaking down fluoropyrimidines. Mutations in the DPYD gene can lead to reduced or absent DPD enzyme activity, resulting in the accumulation of toxic levels of fluoropyrimidines in the body. NGS genetic testing for DPYD gene mutations can help identify individuals who may be at risk for DPD deficiency and may experience severe side effects from fluoropyrimidine-based medications. This information can be used to guide treatment decisions, including dosage adjustments or the selection of alternative medications, to minimize the risk of adverse reactions. It is important to note that DPD deficiency is a rare condition, and not all individuals with DPYD gene mutations will necessarily develop severe side effects. Therefore, the decision to undergo DPYD gene NGS genetic testing should be made in consultation with a healthcare professional who can assess the individual’s specific circumstances and medical history. |
